A plain-language guide to the medications that change the course of MS and NMOSD — what they do, how they work, and what to discuss with your neurologist.
What Are Disease-Modifying Therapies?
Disease-modifying therapies (DMTs) are medications that target the underlying immune mechanisms driving neuroinflammatory disease. Unlike symptom management drugs, DMTs aim to:
- Reduce relapse frequency and severity
- Slow or prevent new lesion formation
- Delay long-term disability progression
They do not repair existing damage or cure the disease — but used early and consistently, they are the most powerful tools available for preserving neurological function.
DMTs for Multiple Sclerosis
MS has the largest and most established DMT landscape, with over 20 FDA-approved options across several categories:
Injectable DMTs (Moderate efficacy, long safety record)
- Interferon beta (Avonex, Betaseron, Rebif, Plegridy) — reduce inflammation and relapse rates by ~30%
- Glatiramer acetate (Copaxone, Glatopa) — modulates immune response; well-tolerated
Oral DMTs (Moderate to high efficacy, convenient)
- Dimethyl fumarate (Tecfidera, Vumerity) — anti-inflammatory and neuroprotective properties
- Fingolimod (Gilenya) — sequesters lymphocytes in lymph nodes, preventing CNS entry
- Siponimod (Mayzent), Ozanimod (Zeposia) — newer S1P modulators with refined profiles
- Teriflunomide (Aubagio) — inhibits rapidly dividing immune cells
- Cladribine (Mavenclad) — short-course oral treatment with durable effects
High-Efficacy Infusion DMTs (Most powerful, used for aggressive MS)
- Natalizumab (Tysabri) — blocks immune cell entry into the CNS; ~68% relapse reduction
- Ocrelizumab (Ocrevus) — targets CD20+ B cells; approved for both RRMS and PPMS
- Ofatumumab (Kesimpta) — self-injectable anti-CD20
- Alemtuzumab (Lemtrada) — depletes and resets immune cells; used in highly active MS
- Ublituximab (Briumvi) — newer anti-CD20 with shorter infusion time
DMTs for NMOSD
NMOSD requires its own targeted therapies — standard MS DMTs can worsen NMOSD and must be avoided.
FDA-approved NMOSD-specific therapies:
- Eculizumab (Soliris) — complement inhibitor; reduces attack risk by ~94% in AQP4+ patients
- Inebilizumab (Uplizna) — targets CD19+ B cells
- Satralizumab (Enspryng) — IL-6 receptor inhibitor; self-injectable
- Rozanolixizumab (Rystiggo) — newer option targeting FcRn receptor
Off-label options used in some cases: rituximab, mycophenolate mofetil, azathioprine.
DMTs for Transverse Myelitis
TM does not have approved DMTs in the same way. Acute treatment focuses on:
- High-dose IV corticosteroids — methylprednisolone to suppress active inflammation
- Plasma exchange (PLEX) — for steroid-unresponsive cases
If TM is associated with MS or NMOSD, the appropriate DMT for that underlying condition is initiated.
Key Considerations When Choosing a DMT
| Factor | Consideration |
|---|---|
| Efficacy vs. risk | Higher efficacy often means more monitoring requirements |
| Route of administration | Injectable, oral, or infusion — lifestyle fit matters |
| Family planning | Many DMTs require washout periods before pregnancy |
| Comorbidities | Liver, cardiac, or immune conditions affect eligibility |
| Monitoring burden | Some require regular MRI, blood counts, or eye exams |
Starting Early Matters
Research consistently shows that early initiation of high-efficacy therapy leads to better long-term outcomes than a "wait and see" or "escalation" approach. Discuss the treat-to-target strategy with your neurologist.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
0 comments